Skip to main content

Table 2 Characterization of designed batches F1 to F9

From: Study of homogenization on media milling time in preparation of irbesartan nanosuspension and optimization using design of experiments (DoE)

Batches

Particle size (nm)

Zeta potential (mV)

PDI

Drug content (%)

F1

291.2 ± 8.88

− 25.89 ± 1.53

0.725 ± 0.21

98.70 ± 0.32

F2

331.0 ± 5.48

− 26.24 ± 0.84

0.596 ± 0.13

98.89 ± 0.62

F3

342.0 ± 11.95

− 27.82 ± 2.13

0.531 ± 0.21

99.10 ± 0.18

F4

320.0 ± 4.87

− 28.45 ± 1.57

0.538 ± 0.12

99.36 ± 0.65

F5

331.0 ± 9.01

− 26.73 ± 0.79

0.417 ± 0.26

98.61 ± 0.90

F6

336.0 ± 4.53

− 28,13 ± 1.16

0.529 ± 0.35

98.74 ± 0.73

F7

228.4 ± 6.93

− 27.32 ± 1.48

0.413 ± 0.29

100.21 ± 0.12

F8

309.0 ± 7.85

− 26.49 ± 1.06

0.399 ± 0.17

99.80 ± 0.35

F9

314.0 ± 6.42

− 27.34 ± 1.77

0.410 ± 0.30

99.56 ± 0.23

  1. Results are average of three readings ± SD